key: cord-0779290-i1ny7s5b authors: Lobinska, Gabriela; Pilpel, Yitzhak; Nowak, Martin A title: Evolutionary safety of death by mutagenesis date: 2022-03-10 journal: bioRxiv DOI: 10.1101/2022.03.10.483790 sha: 6f3855016bfcebaf94eed0f941fb843bf1db4722 doc_id: 779290 cord_uid: i1ny7s5b Nucleoside analogs are a major class of antiviral drugs. Some act by increasing the viral mutation rate causing “death by mutagenesis” of the virus. Their mutagenic capacity, however, may lead to an evolutionary safety concern. We define evolutionary safety as a probabilistic assurance that the treatment will not generate an increased number of epidemiologically concerning mutated virus progeny. We develop a mathematical framework to estimate the total mutant load produced with and without mutagenic treatment. We predict rates of appearance of virus mutants as a function of the timing of treatment and the immune competence of patients, employing various assumptions about the vulnerability of the viral genome and its potential to generate undesired phenotypes. We focus on the case study of Molnupiravir, which is an FDA-approved treatment against COVID-19. We estimate that Molnupiravir is narrowly evolutionarily safe, subject to the current estimate of parameters. Evolutionary safety can be improved by restricting treatment to individuals with a low clearance rate and by designing treatments that lead to a greater increase in mutation rate. We report a simple rule to determine the fold-increase in mutation rate required to obtain evolutionary safety which is also applicable to other pathogen-treatment combinations. Nucleoside analogs are molecules similar in shape to naturally occurring nucleosides used by living organisms and viruses for nucleic acid synthesis. They are therefore readily incorporated into nascent DNA or RNA chains by viral polymerases. Many nucleoside analogs differ from natural nucleosides in key aspects which usually prevents further viral genome chain elongation. Such nucleoside analogues lack a 3'OH group which makes the viral polymerase unable to attach the next nucleoside to the growing chain. Others, such as lamivudine, are D-enantiomers of natural nucleosides, and cause steric hindrance upon incorporation into the DNA or RNA chain 1 . Other nucleoside analogues do not prevent viral transcription. Instead, they have the capacity to ambiguously base pair with several nucleosides. Therefore, they cause erroneous incorporation of nucleosides during the transcription process, thereby increasing the virus mutation rate up to the point of "death by mutagenesis", a mechanism with foundations in quasispecies theory. This theory describes populations of replicating genomes under mutation and selection [2] [3] [4] [5] [6] [7] . Molnupiravir, which has been suggested as treatment against COVID-19, seems to act exclusively through mutagenesis. Its incorporation into nascent RNA genomes by the viral polymerase does not result in chain termination: in fact, the viral RNA polymerase has been shown to successfully elongate RNA chains after the incorporation of Molnupiravir [8] [9] [10] . Molnupiravir switches between two tautomeric forms: one is structurally similar to a cytosine, the other is structurally similar to a uracil. Hence, Molnupiravir can base pair, depending on its form, either with guanosine or with adenosine 8, 9 . SARS-COV2 is a positive-sense single-stranded RNA virus and its RNA replication proceeds in two steps. First, the negative-sense RNA is polymerized based on the plus strand, and the negative strand then serves as a template to synthetize positive-sense RNA molecules 11 . Hence, the incorporation of Molnupiravir during the first step of RNA synthesis gives rise to an ambiguous template: positions where Molnupiravir was incorporated can be read by the RNAdependent RNA polymerase as either guanosine or adenosine. This causes mutations in the progeny RNA compared with the parental RNA, possibly up to the point of the "error catastrophe" and death of the virus [8] [9] [10] . While considerable theoretical basis describes death by mutagenesis, a theoretical treatment is still missing to describe quantitatively the potential of emergence of variants of concern (VoC) upon mutagenesis. For example, in the context of the COVID-19 pandemic, the mutagenic potential of Molnupiravir naturally causes concerns about accelerating SARS-COV2 evolution. The evolution of resistance of SARS-COV2 against vaccination or existing treatments as well as enhanced transmissibility or lethality is a major concern, which has given rise to an impressive number of studies [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] that have been founded on a long history of modelling the emergence of resistance against treatment in other viruses 28-36 and epidemiological models for disease spread 18, 19, 37, 38 . As noted before, the intended antiviral activity of Molnupiravir resides in its capacity to induce mutagenesis and hence reduce virus load. Yet, this very property which confers to Molnupiravir its desired antiviral effect might also enhance the capacity of the virus to develop drug resistance, immune evasion, infectivity or other undesired phenotypes. Thus, a mathematical analysis should weigh the desired and potentially deleterious effects of mutagenesis drugs in general, and of the present virus and drug in particular. In this paper, we analyze the case study of the increase of the evolutionary potential of a virus (here: SARS-COV2) under mutagenic treatment (here: Molnupiravir treatment). In particular, we ask if the wanted effect of limitation of virus load by the drug could be accompanied by an unwanted enhancement in the rate of appearance of new VOCs due to increased mutagenesis. We construct a mathematical framework describing the increase and decrease of the virus load after infection and derived expressions for the total amount of wild-type and mutant produced by individuals during the course of an infection. We use empirical data on COVID-19 and bioinformatic data on SARS-COV2 to estimate key parameters, including infection progression within the body amidst response of the immune system and the number of potentially lethal positions in the genome. We find that the Molnupiravir-SARS-COV2 couple is situated in a region of the parameter space which is narrowly evolutionarily safe. Evolutionary safety increases with decreasing clearance rate in treated patients and with higher number of viral genome positions that are lethal when mutated. Crucially, evolutionary safety could be improved by obtaining higher increases in the mutation rate under treatment which provides a clear direction for drug improvement. We suggest a simple mathematical formula which determines the evolutionary safety of a drug given the pathogen's mutation rate with and without treatment and the number of positions in the pathogen's genome that are lethal when mutated. After infection with SARS-COV2, virus load increases exponentially until it reaches a peak after a median of about 5 days 39 . During this growth phase the action of the immune system is insufficient to counterbalance viral replication. Subsequently the immune response gains momentum and infection enters a clearance phase. Now virus load decreases exponentially until the virus becomes eliminated about 10-30 days after initial infection 35,39 . In some immunocompromised individuals, viral clearance can take many weeks 40,41 . However, some argue that the isolation of infectious virus is rare after 20 days post-infection 42 . In our mathematical formalism, we describe the evolution of a virus within the body of a single human host by following the abundance of two viral types: wild type, , and concerning mutants, . Concerning mutants are those that can lead to undesirable viral evolution, for example to escape from vaccination 14 or toward higher virulence or infectivity. Later we broaden the definition of variable to include any viable mutant, as these may subsequently facilitate epistatic tracks towards to VOCs. Both and replicate with birth rate and replication quality = 1 − , where is the mutation rate per base. The mutation rate can be altered by the administration of a mutagenic drug. The virus genome contains positions, all of which must be maintained without mutations in order to generate viable progeny. We consider positions, such that even a single mutation in one of them gives rise to a concerning mutant virion, . As common in mutagenesis and also in the specific mechanism of action of Molnupiravir, transition mutations are more likely than transversion mutations (see Figure 1A ). Our model can be extended to consider situations where the mutagenic drug increases the probability of mutation for a subset of all possible mutations (see Methods). Both and are cleared at same rate with the subscript indicating the presence or absence of an adaptive immune response. During the growth phase = 0 and during the clearance phase = 1. We have 0 < < 1 . Virus dynamics 43 in an infected patient can be described by the system of differential equations We ignore back mutation from mutant to wild type 2, 5, 43 . In the growth phase, without treatment, we have + > 0 since both and grow exponentially. In the clearance phase, without treatment, we have < 1 since both and decline exponentially. The system is linear and can be solved analytically (see Methods). The biological reactions are presented schematically in Figure 1B . In our simple approach, there is a sudden onset of adaptive immunity which happens at time . We relax this assumption in a model extension. All parameters and methods for their estimation are summarized in Table 1 . Each parameter can be estimated from existing literature. We denote by 0 the mutation rate without mutagenic treatment and by 1 , which is greater than 0 , the mutation rate with mutagenic treatment. The typical mutation rate for other positive single-strand RNA viruses is 10 −544 . The mutation rate of SARS-COV2 has been hypothesized to be lower because of a proofreading capability 45 . The per-base mutation rate has been estimated at 0 = 10 −6 by proxy with the related betacoronavirus MHV 46,47 . An in vitro study of experimental evolution of SARS-COV2 has reached the estimate 0 = 3.7 • 10 −648 . Another study measuring the mutation rate of SARS-COV2 in vitro has estimated 0 = 2.5 • 10 −510 . For our analysis, we use 0 = 10 −6 . The mutation rate of SARS-COV2 under Molnupiravir treatment has been measured in vitro to be 2 to 5-fold higher than without treatment 10 Estimation of the number of viral genome positions that are either lethal or potentially concerning when mutated The distribution of fitness effects of random, single mutations has been studied in a different single-stranded RNA virus, the vesicular stomatitis virus (VSV) 52 . This distribution seems to be similar among single-stranded RNA viruses but could differ between species 53 . According to these studies, the proportion of viral genome positions that are lethal when mutated is about 40% and the proportion of highly deleterious mutations, defined as those that reduce the viral fitness by more than 25%, represents about 30%. Note that the small mutation rate allows us to approximate the number of lethal positions as 1/3 of the total number of possible mutations, taking into account that each position can be mutated to three different destinations. SARS-COV2 genome has a length of 29,900 nt. Hence, we have = 11,960 when considering lethal mutations only and = 20,930 when considering both lethal and highly deleterious mutations. Hence, the realistic range for is between 11,960 and 20,930. For completeness, we also explore unrealistically low values of such as 1,500, which is the number of positions in the coding genome that are one nucleotide way from a STOP codon. In order to estimate the number of positions that could give rise to new variants of concern when mutated (denoted by ), we used empirical data collected by 54 Of course, mutations that are advantageous for the virus could occur also outside of the receptorbinding domain of the spike protein. More broadly, any neutral and even slightly deleterious mutation can be undesirable since they could represent an evolutionary "stepping-stone" to a multiple-mutation variant due to epistasis. Hence, we also explore how considering a very large number of positions that could give rise to new variants of concern when mutated, up to the length of the SARS-COV2 genome minus the positions that are lethal when mutated. In Figure 2 , we show the dynamics of total virus and mutant over the course of an infection. We consider four times for the start of mutagenic treatment: at infection; at day 2 after infection, which corresponds to the beginning of symptoms; at day 5 after infection, which corresponds to the peak of the virus load; and at day 7 after infection. We observe that treatment always decreases the abundance of wild type virus. The dynamics of mutant follows that of the wild type. For the parameters used in Figure 2 , treatment decreases the abundance of mutant virus -with exception of a brief transient period soon after the start of therapy, which is almost invisible in the figure. We are now interested in calculating the total number of mutant virus produced over the course of infection. This number can be computed as the integral of the abundance of mutant virus over time (see Methods). We consider two scenarios: in the first, the patient begins treatment when their virus load reaches its peak; in the second, the patient begins treatment when they become infected (following exposure to an infected individual). In Figure 3 , we show the cumulative mutant load, ( 1 ), as a function of the mutation rate 1 for the case where treatment starts at peak virus load. To understand this function, we introduce the parameter = / , with and denoting respectively wildtype and mutant virus load at peak, which is reached for each strain at a time. If > / then ( 1 ) is a declining function. In this case, any mutagenic treatment is evolutionarily safe in the sense of reducing the cumulative mutant virus load. If on the other hand < / then the function ( 1 ) attains a single maximum at * = 1 − − + If 0 > * then any increase in mutation rate is beneficial as it actually decreases the chance of appearance of VOC compared to evolution of the virus under no treatment. If 0 < * then a small increase in the mutation rate can increase the chance of appearance of VOC under treatment, and thus be evolutionarily unsafe; in this case there needs to be a sufficiently large increase in mutation rate to make the treatment evolutionarily safe (see Figure 3 for details). We notice that increasing estimates of or decreasing 1 reduces the value of * and therefore increases the range of 0 for which mutagenic treatment is evolutionarily safe. In particular, the more immunocompromised a patient is (lower 1 ), the lower the value of * . In Figure 3 , we notice that only for low and high 1 we find * > 0 . For all other cases, * > 0 , and death by mutagenesis is both evolutionarily safe and evolutionarily desired, because it reduces the abundance of both wild type and mutant. In Figure 3 , we also show the cumulative mutant load, ( 1 ), as a function of the mutation rate 1 for the case where treatment starts at infection. We find that this function attains a maximum at a value which is given by the root of a third order polynomial (see Methods and Extended Data Again if 0 > * then any increase in mutation rate is beneficial. If 0 < * then a small increase in the mutation rate can be evolutionarily not safe, but a sufficiently large increase in mutation rate can make the treatment evolutionarily safe (see Figure 3 for more details). Exploring the parameter space for evolutionary safety In Figure 4 , we show the fold-increase in virus mutation rate that mutagenic treatment has to achieve to be evolutionarily safe. We vary first the number of lethal mutations in the viral genome and the clearance rate 1 . For treatment starting at peak virus load (Figure 4A) , we find that increase in mutation rate is evolutionarily safe if > 22,000 or 1 < 7.8 (green region). Evolutionary safety becomes an issue for small values of and larger values of 1 . For = 12,000 and 1 = 9 we need at least a 10-fold increase in mutation rate before the drug attains evolutionary safety. When treatment begins at infection ( Figure 4B ) the evolutionarily safe area becomes smaller, but the minimum increase in mutation rate required for evolutionary safety is lower. For example, for 1 = 9 and = 12,000, we need only a 3-fold increase. We show the same figure, but for an extended range of values in Extended Data Figure 2 . Evolutionary risk factor (ERF) and infectivity risk factor (IRF) We define the "evolutionary risk factor" (ERF) of mutagenic treatment as the ratio of cumulative mutant virus load with treatment compared to without treatment (see Methods). The condition for evolutionary safety of mutagenic treatment is that ERF is less than one. Denote by the cumulative mutant load with the subscript indicating the presence ( = 1) or absence ( = 0) of treatment during the growth phase, and the subscript indicating the presence ( = 1) or absence ( = 0) of treatment during the clearance phase. Therefore, 00 is the cumulative mutant load without treatment, 01 is the cumulative mutant load with treatment in the clearance phase, and 11 is the cumulative mutant load with treatment in both growth and clearance phase. For treatment that starts at peak, = 01 / 00 . For treatment that starts at infection, = 11 / 00 . An evolutionary risk factor below one signifies that treatment reduces the mutant load, and hence treatment can be even encouraged from an evolutionary perspective. An evolutionary risk factor above one implies that treatment increases the mutant load. In addition, we define the "infectivity risk factor" (IRF) which quantifies the efficacy of the treatment. The IRF is the ratio of the total cumulative viral load, mainly governed by the wildtype, with treatment compared to the total cumulative viral load without treatment. IRF is always below 1. In Table 2 , we computed some values for the cumulative mutant load with and without treatment and the cumulative total virus load with and without treatment, as well as the corresponding ERF and IRF. We notice that ERF increases (hence evolutionary safety decreases) with clearance rate, absolute quantity of mutant produced is lower. We also notice that the IRF increases with immunocompetence, indicating that the benefit of treatment is smaller for more immunocompetent individuals who clear the virus rapidly. In Figure 5 and Extended Data Figure 3 , we explore the ERF for wider regions of the parameter space. We vary each pair of parameters, while fixing others at their most probable value. The ERF exceeds 1 when the number of positions that would be lethal when mutated is much lower than our minimum estimate ( < 12,000). As decreases treatment induces less death by mutagenesis and thus provides more opportunity for mutants to be generated and to survive. Again, we observe that evolutionary safety decreases with the clearance rate, 1 In Extended Data Figure 4 , we explore the ERF for lower and higher values of the birth rate and the clearance rate 0 in the growth phase. We adjust the values of and 0 such that the net growth rate is conserved (ignoring lethal mutations). We observe that smaller values of and 0 lead to an increase in ERF, while larger values to a decrease. The evolutionary risk factor is a slowly declining function of the number of concerning mutations So far, we have used the parameter to denote the number of mutations which would result in variants of concern (VOCs) that is variants with increased transmissibility, virulence or resistance to existing vaccines and treatments. However, in the broad sense, any treatment which increases the standing genetic variation of the virus could favor the emergence of new variants of concern by enabling epistatic mutations. Therefore, we now extend the interpretation of to include any viable mutation in the viral genome. In Figure 6 , we show that the ERF is a declining function of . Thus, the more opportunities the virus has for concerning mutations (the larger ), the higher the advantage of mutagenic treatment. The reason for this counter-intuitive observation is that for large the cumulative mutant virus load is high already in the absence of treatment, while mutagenic treatment reduces the mutant load by forcing additional lethal mutations. ERF decreases with the number of positions also for lower birth rate (Extended Data Figure 5 ). Advantageous mutants do not substantially affect the evolutionary safety compared to neutral mutants Concerning mutants could have an in-host advantage compared to wild type, such as faster a reproductive rate or a lower clearance rate. In Extended Data Figure 6 , we evaluate a mutant with a 1% selective advantage in birth rate. As expected, we observe that the advantageous mutant reaches higher virus load than a neutral mutant. But we also observe: if there is a minimum increase in mutation rate that is required for evolutionary safety, then it is lower (or slightly lower) for the advantageous mutant. Therefore, a treatment that is evolutionarily safe for a neutral mutant is also evolutionarily safe for an advantageous mutant. Gradual activation of the immune system As before = 7.61, = 5 and 0 = 10 −6 . For = 3 fold-increase of mutation rate induced by mutagenic treatment, we get > 14,455. Since evolutionary safety improves with decreasing clearance rate 1 (in the full model) we can interpret inequality (4) as a sufficient condition or as an upper bound. The agreement between the analytical formulas and the numerical computation of the model is shown in Extended Data Figure 9 . For the simplified model, we also find that ERF is a declining function of the number of concerning mutations, (see Extended Data Figure 10 ). We provide a mathematical framework to compute the evolutionary risk factor of death caused show that the value of m is below 12,000, then we predict that the evolutionary risk factor of Molnupiravir exceeds 1 and hence the treatment could increase the rate of appearance of new VOCs. We therefore advocate caution when drawing conclusions about Molnupiravir's safety. However, our analysis has also identified parameters which will not affect appreciably the assessment of evolutionary safety of Molnupiravir, such as the number of positions that are able to give rise to new variants of concern. Our analysis has also provide a simple rule (eq 4) for evolutionary safety of mutagenic treatment. We anticipate that additional "death by mutagenesis" drugs will emerge, and their evolutionary safety will need to be assessed before making them available for treatment. The safety concerns that emerge from the use of a mutagenic drug extend beyond the increased Our code for mathematical simulations is available at https://github.com/gabriela3001/molnupiravir_evol_safety. No biological data were generated during this project. We denote by and the abundances of wild type and mutant virus in an infected person. Evolutionary dynamics can be written as The in the viral genome leading to concerning mutations is given by . Therefore, measures the abundance of concerning mutants in a patient. At first, we assume that those mutations are neutral in the sense of having the same parameters and as the wild type virus in the patient in which they arise. We note that in Eq. (5) the mutant is mildly advantageous because > + . We assume that the adaptive immune response begins days after infection, at which time the clearance rate of the virus increases from 0 to 1 . Therefore, peak virus load is reached at time . For exponential increase in virus load during the growth phase, which occurs during the first days of infection, we require 0 + > 0 . For exponential decrease in virus load during the clearance phase, we require 0 < 1 . Using = + for the total virus abundance we obtain Eq (6) is the same as Eq (5a) but occurs instead of + . In the following we derive results for . The corresponding results for are obtained by replacing with + . Results for are given by − . During the growth phase, we have ̇= ( − 0 ). For initial condition = 1 we get The cumulative amount of virus produced until time is The growth phase ends at time , at which point the virus abundance is We use and the corresponding quantities and as initial conditions for the clearance phase. For the clearance phase, which starts at time , we have ̇= − ( 1 − ). Using initial condition we obtain The cumulative virus during the clearance phase is given by For the cumulative virus load of growth plus clearance phase we obtain Let us use to denote the cumulative virus during the entire infection where = 0 or = 1 indicates absence or presence of treatment during the growth phase and = 0 or = 1 indicates absence or presence of treatment during the clearance phase. We have The corresponding equation for the cumulative wild type virus is The corresponding equation for the cumulative mutant virus is given by the difference Without any treatment the cumulative mutant virus is 00 . If treatment starts at at time the cumulative mutant virus is 01 . If treatment starts at time 0 the cumulative mutant virus is 11 . Mutagenic treatment increases the mutation rate of the virus from 0 to 1 and therefore reduces the replication accuracy from 0 to 1 . We have 0 < 1 and 0 > 1 . We define the evolutionary risk factor, , of mutagenic treatment as the ratio of cumulative mutant virus load with treatment over the cumulative mutant virus load without treatment. For treatment that starts at time , we have = 01 / 00 . For treatment that starts at time 0, we have = 11 / 00 . The quantifies how safe or unsafe a mutagenic treatment is. If < 1 then the treatment is evolutionarily safe. We define the infectivity risk factor, , of mutagenic treatment as the ratio of cumulative virus load with treatment over the cumulative virus load without treatment. For treatment that starts at time , we have = 01 / 00 . For treatment that starts at time 0, we have = 11 / 00 . The cumulative virus during the clearance phase with treatment is The cumulative wild type virus during the clearance phase with treatment is The cumulative mutant virus during the clearance phase with treatment is We use from above = ( 0 − 0 ) and = ( 0 + − 0 ) . Clearly, The function − ( 1 ) has the following behavior: (1) If > / then − ( 1 ) is a declining function. In this case, mutagenic treatment is always beneficial. (2) If < / then − ( 1 ) has a single maximum which is attained at * = 1 − − + If 0 > * then any mutagenic treatment is beneficial. If 0 < * then mutagenic treatment needs to be sufficiently strong to be beneficial; in this case, we need − ( 0 ) > − ( 1 ). For small 0 the condition > / is equivalent to > 1/( 0 ). For relevant parameters, the cumulative mutant virus load 11 ( 1 ) -given by Eq. (15) -as a function of the mutation rate during treatment attains a single maximum at a value * . If 0 > * then mutagenic treatment is always beneficial. If 0 < * then mutagenic treatment needs to be sufficiently strong to be beneficial; specifically, we need 11 ( 0 ) > 11 ( 1 ). We obtain * as follows. Let = . We find * = * as the solution of the polynomial: ( ) = ℎ + − (ℎ 2 + 2 ) − 2 ℎ (2ℎ + ) − 3 ℎ 2 2 Here We now consider the effect of mutagenic treatment in a setting that uses further simplification. We only study the amount of virus that is generated during the growth phase with and without mutagenic treatment. As before we have: For the total virus, = + , we have: We use = 0 = 1 − 0 to denote absence of treatment and = 1 = 1 − 1 to denote presence of treatment, with 1 > 0 . In the absence of treatment, we assume 0 + > which means the wild type can expand. Clearly, the aim of mutagenic treatment is to eradicate the infection, that is to prevent the exponential expansion. Thus, mutagenic treatment succeeds if 1 < . In other words, the mutation rate induced by mutagenic treatment should satisfy Using our SARS-Cov2 estimates, = 20,000, = 7.6 and = 3, we obtain 1 > 4.65 • 10 −5 . If the natural mutation rate is 10 −6 then -ideally -we are looking for a mutagenic drug that achieves a 50-fold increase in mutation rate. If the mutagenic drug is less powerful, then it does not prevent the infection, but it could still reduce both virus load and mutant virus load. In this case a more complicated calculation is needed. For initial condition = 1 ( = 1 and = 0) we obtain at time We need to understand how behaves as a function of the mutation rate. For this analysis, the parameter is irrelevant, because we can write We find that ( ) is a one-humped function with a single maximum near * = 1 This approximation holds for * << 1. Increasing , , or reduces the value of * . If 0 is greater * then any increase mutation rate reduces the amount of mutant virus. Using our SARS-Cov2 estimates, = 20,000, = 7.6 and = 5, we obtain * = 1.31 • 10 −6 . This value is very close to the estimate for the normal mutation rate 0 = 10 −6 . If 0 is less than * then we need to calculate the ERF to evaluate if the treatment reduces the amount of mutant virus. We Notice that cancels out and the parameters and appear as the product ℎ = . We obtain For small ℎ we can approximate −ℎ ≈ 1 − ℎ , and therefore We find The key parameter, ℎ = , is the number of replication events between the infecting virion and those virions that are present at the time of evaluation; using = 7.61 and = 5 we have ℎ = 38.05. For 0 = 10 −6 and = 3 fold-increase induced by mutagenic treatment, we get > 14,455. For = 2 we get > 18,217. Defining the infectivity risk factor, , as 1 ( )/ 0 ( ) we obtain Using the approximation = (1 − ) ≈ 1 − we have We note that IRF is always less than 1. Molnupiravir is molecularly similar to a cytosine, however it can base-pair equally efficiently with both adenosine and guanosine. Hence, the probability of certain possible mutations will be increases more than others. Specifically, in the case of molnupiravir, transition mutations will be more frequent, but transversion mutations are not expected to increase. If the mutagenic drug increases the mutation rate in a fraction of positions, evolutionary dynamics can be written as Hence, we have: which is equivalent to Eq. 5. Hence all the subsequent derivations hold. (1) . Its replication proceeds by two steps: first, the synthesis of a negative-sense template strand (2) , which is then used to synthesize a positive-sense progeny genome (3). Molnupiravir (designated by M) is incorporated against A or G during the synthesis of the negative-sense template strand (2) . When the template strand is replicated, M can be base-paired with either G or A. Hence, all A and G in the parent genome become ambiguous and can appear as A or G in the newly synthetized positive-strand genome; see position 1 in (3). C and T are not affected by molnupiravir during the synthesis of the template strand, (1) to (2) , but can be substituted to M during the synthesis of the progeny genome from the template strand; see (2) to (3) . As previously, M can then base-pair with A or G when used as a template; see (3) to (4), which can cause A->U and U->A transitions in the final progeny genome (5) . B: Virus dynamics within an infected person. Wildtype ( ) and the mutant ( ) replicate at rate and quality = 1 − . The per base mutation rate, , is increased by treatment with molnupiravir. Both the wildtype and the mutant need to maintain positions to remain viable. Mutating any of positions in the wildtype results in a mutant. In the beginning of the infection, the adaptive immune response is weak, and the virus is cleared at a rate 0 which is less than . After some time, , the adaptive immunity is strong, and the virus is cleared at the higher rate , during treatment. The cumulative mutant virus load increases with mutation rate 1 before reaching a peak and then decreases to low values. If the peak is reached at a mutation rate that is less than the natural mutation rate, 0 (red dotted line), then any increase in mutation rate reduces the cumulative mutant load. If the peak is reached for a mutation rate greater than 0 , then the increase in mutation rate caused by mutagenic treatment must exceed a threshold value (blue dotted line) to reduce the cumulative mutant virus load. The hypercycle. A principle of natural self-organization. Part A: Emergence of the hypercycle Self-replication with errors. A model for polynucleotide replication A localization threshold for macromolecular quasispecies from continuously distributed replication rates Error thresholds of replication in finite populations mutation frequencies and the onset of Muller's ratchet What is a quasispecies? Examining The Theory of Error Catastrophe Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells Coronavirus biology and replication: implications for SARS-CoV-2 Modeling within-host sars-cov-2 infection dynamics and potential treatments Revisiting the guidelines for ending isolation for COVID-19 patients Evolution of resistance to COVID-19 vaccination with dynamic lockdown Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science (80-. ) Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years On the relationship between serial interval, infectiousness profile and generation time Quantifying the impact of quarantine duration on covid-19 transmission Network models and the interpretation of prolonged infection plateaus in the COVID19 pandemic Effect of human behavior on the evolution of viral strains during an epidemic Individual risk-aversion responses tune epidemics to critical transmissibility Tables Symbol Name Value Method of Table 2 . Cumulative virus load, mutant load, infectivity risk factor (IRF) and evolutionary risk factor (ERF) of mutagenic treatment. (A) Treatment starts at peak virus load. (B) Treatment starts at infection. We show numerical results for individuals that differ in their immune competence, which affects the clearance rate, 1 , during adaptive immunity. Patients that are less immunocompetent benefit more from mutagenic treatment (lower IRF) and also have a lower ERF. Parameters: 0 = 3, = 7.61, 0 = 10 −6 , 1 = 3 • 10 −6 , = 20,000, = 1, = 5. Initial condition: 0 = 1 and 0 = 0.